Hormonal
Enobosarm (3-6 mg/day) preserves total lean mass and reduces fat mass loss when co-administered with semaglutide for weight loss in older adults with overweight/obesity, without compromising overall body weight reduction.
If you are taking semaglutide for weight loss and are concerned about losing muscle, ask your doctor about adding enobosarm (3-6 mg daily). Recent Phase 2b data suggests this combination preserves lean mass and increases fat loss compared to semaglutide alone, without changing total weight loss. Note that this specific combination is still under regulatory review and not yet approved.
Top-line company communications (no peer-reviewed publication yet) report that the combined treatment with semaglutide and enobosarm met the primary endpoint of preservation of total lean mass at 16 weeks vs. semaglutide + placebo (71% relative reduction in lean mass loss; the 3 mg dose ~99% preservation; p ≤ 0.002)... Interestingly, fat mass loss was greater with enobosarm... although the overall body weight loss was similar to semaglutide alone—that is, more fat, less muscle lost on the combined treatment with semaglutide and enobosarm.
Why this rating
The data comes from 'top-line company communications' and press releases, not yet peer-reviewed publications, indicating preliminary but not fully validated evidence.
Source
Enobosarm in Muscle Wasting
Stephan von Haehling · JCSM Communications · 2026
DOI 10.1002/rco2.70027
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →